Reduced THRSP in adipose tissue is linked to metabolic syndrome and impaired mitochondrial function .
Insulin upregulates THRSP in adipocytes, enhancing lipid storage and glucose metabolism .
THRSP overexpression reverses lenvatinib resistance in HCC by suppressing glycolysis via ENO2 downregulation .
Recombinant THRSP protein (20.3 kDa, His-tagged) is available for research, enabling functional studies .
Lipid Metabolism: Co-expressed with FASN, ACACA, and ELOVL6; enriched in KEGG metabolic pathways .
Immune Modulation: Low THRSP associates with B-cell and CD4+ T-cell infiltration in HCC .
THRSP (thyroid hormone responsive) maps to chromosome 11 (NC_000011.9) in the region between 77774907 and 77779307 on the plus strand and spans approximately 5.6 kilobases. The gene consists of two exons measuring 481 and 603 bp, with only the smaller exon being translated. The coding region of human mRNA for THRSP contains 438 nucleotides, and the complete mRNA (NM_003251.2) spans 1084 nucleotides .
When analyzing THRSP genomic structure in new experimental settings, researchers should use current genomic alignment tools such as Spidey (mRNA to genomic sequence alignment) to verify exon boundaries, particularly in different tissue types where alternative splicing might occur.
THRSP transcription is regulated through multiple mechanisms:
Hormonal regulation: Thyroid hormone, insulin, and progestin can induce THRSP expression
Nutritional factors: Carbohydrate intake (particularly glucose) upregulates THRSP
Developmental processes: THRSP is induced during adipose tissue differentiation and lactation
Inhibitory factors: Glucagon and conjugated linoleic acid inhibit THRSP expression
Insulin signaling pathway: Insulin increases THRSP mRNA expression approximately 5-8 fold after 180-360 minutes of euglycemic hyperinsulinemia through a phosphoinositide 3-kinase (PI3K)-dependent mechanism
When designing experiments to study THRSP regulation, researchers should control for these variables and consider using time-course studies to capture the dynamic regulation patterns.
THRSP plays a crucial role in lipid metabolism through several mechanisms:
It exists as a heterodimer in human cells actively synthesizing lipids
Its expression pattern parallels that of fatty acid synthase (FASN) in adipose, liver, and mammary tissues
Inhibition of THRSP via siRNAs or antisense RNAs reduces expression of genes encoding lipid-synthesizing enzymes
THRSP interference in mesenchymal stem cells significantly reduces lipid droplet formation
Key regulators of adipogenesis (LPL, FABP4, PLIN1, CIDEC) are downregulated following THRSP silencing
THRSP appears to regulate endoplasmic reticulum stress and the PPAR signaling pathway, which are closely related to lipid synthesis and metabolism
Research methodologies should incorporate lipidomic analyses alongside gene expression studies to comprehensively assess THRSP's impact on lipid profiles.
THRSP is highly conserved across mammalian species with varying degrees of homology:
Three domains are conserved from the ancestral S14-related peptide (Strait 11499, Mig12, S14-related protein) . When conducting comparative studies, researchers should focus on these conserved domains and consider structural modeling approaches to identify functional similarities despite sequence variations.
Based on current research approaches:
qPCR: For accurate quantification of THRSP mRNA levels in tissue samples and cell lines
Lentiviral transfection: To establish stable cell lines overexpressing THRSP
shRNA technology: For effective THRSP silencing in functional studies
Transcriptomic analysis: RNA-seq to identify downstream targets and pathways
Proteomic analysis: To complement transcriptomic data for comprehensive pathway analysis
For reliable results, researchers should include appropriate housekeeping genes as controls and validate findings using multiple techniques.
THRSP silencing has significant effects on mitochondrial function and metabolism:
Transcriptomic analysis of THRSP-silenced adipocytes reveals substantial alterations in mitochondrial functions and lipid metabolism pathways
Functional assays demonstrate impaired mitochondrial respiration following THRSP silencing
Fatty acid oxidation is significantly reduced in THRSP-silenced cells
Lipidomic analysis shows altered sphingolipid metabolism, particularly decreased hexosylceramide concentrations
Expression levels of enzymes regulating sphingolipid metabolism are affected
Key genes in lipid droplet generation (LIPE, DGAT1, AGPAT2) are significantly downregulated
Methodological approach: Researchers investigating this relationship should employ comprehensive metabolic phenotyping including:
Seahorse XF analysis for mitochondrial respiration
Radioisotope-labeled substrate studies for measuring fatty acid and glucose metabolism
Integrated transcriptomic and lipidomic analyses
The relationship between THRSP and cancer appears to be tissue-specific:
THRSP exhibits decreased expression in HCC tissues compared to adjacent healthy tissues
Patients with lower THRSP protein and mRNA expression demonstrate worse clinical outcomes
THRSP knockdown increases cell growth, migration, and invasion of HCC cells
THRSP overexpression exerts anti-tumor effects both in vivo and in vitro
Mechanistically, THRSP inhibits epithelial-to-mesenchymal transition through the ERK/ZEB1 signaling pathway
Elevated expression of THRSP in human breast tumors correlates with poor prognosis
Absence of THRSP expression is associated with longer survival
Research methodology: Studies on THRSP in cancer should include:
Patient-derived xenograft models
Analysis of large patient cohorts with long-term follow-up
Pathway validation using multiple inhibitors/activators
Integration of clinical data with molecular findings
Research demonstrates a significant relationship between insulin sensitivity and THRSP expression:
THRSP induction by insulin is impaired in insulin-resistant subjects
THRSP expression correlates closely with whole-body insulin sensitivity measured by euglycemic insulin clamp technique
In vivo studies show that insulin increases THRSP mRNA expression 5-fold after 180 minutes and 8-fold after 360 minutes of euglycemic hyperinsulinemia
This regulatory mechanism depends on the phosphoinositide 3-kinase (PI3K) pathway
Experimental approach for researchers:
Euglycemic insulin clamp paired with adipose tissue biopsies
In vitro adipocyte models with induced insulin resistance
Time-course analyses to capture dynamic expression changes
Pathway inhibitor studies to confirm signaling mechanisms
Integrative multi-omics approaches provide the most comprehensive understanding of THRSP function:
Combined transcriptomic and proteomic analyses reveal that differential genes/proteins following THRSP interference are enriched in:
Transcriptomic analysis identifies ATF6 (endoplasmic reticulum stress marker gene) as the most significantly downregulated transcription factor following THRSP interference
Lipidomic analysis complements these findings by identifying specific lipid species affected by THRSP alterations, such as decreased hexosylceramide concentrations
Recommended methodological framework:
RNA-seq for comprehensive transcriptome profiling
Quantitative proteomics using DIA (Data-Independent Acquisition)
Targeted lipidomics focusing on sphingolipids and glycerophospholipids
Metabolomics to identify metabolic pathway changes
Integrative bioinformatics approaches to identify convergent pathways
Different experimental models offer distinct advantages for tissue-specific THRSP research:
Simpson-Golabi-Behmel syndrome (SGBS) adipocytes provide a reliable human adipocyte model
C3H10 mouse mesenchymal stem cells allow for adipogenic differentiation studies
Patient-derived xenograft models
3D tumor spheroid cultures
Euglycemic insulin clamp with tissue biopsies in human subjects
Transgenic mouse models with tissue-specific THRSP alterations
The interplay between thyroid hormones and insulin in regulating THRSP expression is complex:
Both thyroid hormones and insulin independently induce THRSP expression
Thyroid hormones regulate THRSP via thyroid hormone response elements in the promoter region
In conditions of insulin resistance, the induction of THRSP by insulin is significantly impaired
The timing of expression differs: insulin effects are observed within hours, while thyroid hormone effects may take longer
Experimental methodology for investigating this interaction:
Sequential and combined hormone treatments with time-course analysis
Chromatin immunoprecipitation (ChIP) to identify binding of thyroid hormone receptors and insulin-responsive transcription factors
Promoter mutation studies to identify critical regulatory elements
Studies in models with selective hormone receptor deficiencies
Recent evidence suggests important connections between THRSP and endoplasmic reticulum (ER) stress:
Transcriptomic and proteomic analyses show THRSP interference affects ER stress pathways
ATF6, a key marker gene for ER stress, is significantly downregulated following THRSP interference
This relationship may explain how THRSP influences lipid metabolism, as ER stress is closely linked to lipid synthesis and metabolism disorders
The PPAR signaling pathway, which is affected by THRSP levels, also intersects with ER stress responses
Recommended research approach:
Monitor expression of key ER stress markers (GRP78, CHOP, XBP1 splicing) following THRSP modulation
Use specific ER stress inducers (tunicamycin, thapsigargin) with and without THRSP modulation
Apply proximity ligation assays to identify direct protein interactions
Measure calcium flux and ER morphology to assess functional consequences
TSH is a glycoprotein hormone composed of two subunits: alpha (α) and beta (β). The alpha subunit is common to other glycoprotein hormones like luteinizing hormone (LH) and follicle-stimulating hormone (FSH), while the beta subunit is unique and confers biological specificity. The recombinant form of TSH is produced by co-transfecting a human α-subunit cDNA with a human β-subunit partial genomic clone into Chinese Hamster Ovary (CHO) cells .
The production of rhTSH involves several steps:
Recombinant human TSH is primarily used in the management of thyroid cancer. It stimulates the uptake of radioactive iodine (131 I) and the release of thyroglobulin (Tg) from thyroid remnants and metastases, aiding in the detection and treatment of thyroid carcinoma . Additionally, rhTSH is used in diagnostic tests to evaluate thyroid function without the need for patients to discontinue thyroid hormone therapy .